TNF Pharmaceuticals ramps R&D, sells securities amid cash burn, dilution and Nasdaq risk

Company: TNF Pharmaceuticals, Inc. (NASDAQ: MYMD)

Quick read - what's happening inside
Management is spending heavily to advance Isomyosamine and Supera‑CBD (Phase 2b activity noted), cutting headcount to lower G&A while ramping R&D. The balance sheet shrank during H1 2025 as marketable securities were liquidated to fund operations. The company remains loss-making and dependent on new financing; auditors/management disclose substantial doubt about going concern. The company also faces a Nasdaq minimum‑bid deficiency.

Key facts & stats
- Cash: $207,553 (June 30, 2025) - up from $173,154 at Dec 31, 2024
- Marketable securities: $3,605,508 (down from $8,345,082)
- Total assets: $17,151,103 (vs. $21,421,084)
- Working capital: $(397,585) (Current assets $5,152,564 vs. Current liabilities $5,550,149)
- Stockholders' equity: $5,277,287 (vs. $9,789,740)
- Accumulated deficit: $(133,849,089)
- Net loss (three months ended June 30, 2025): $(1,796,195); six months: $(2,920,938)
- Net loss attributable to common stockholders (three months): $(2,772,564); six months: $(4,710,803)
- Basic & diluted loss per common share: $(0.18) (quarter); $(0.45) (six months)
- Weighted average common shares (basic & diluted): 15,698,856 (quarter); 10,552,848 (six months)
- Product revenue: $0 (no commercial revenue)
- R&D expense: $873,472 (quarter); $2,418,985 (six months) - up materially year‑over‑year
- G&A expense: $894,297 (quarter); $1,735,982 (six months) - down vs prior year periods
- Preferred stock dividends: $976,369 (quarter); $1,789,865 (six months)
- Marketable‑securities sales proceeds (six months): $10,659,546; purchases $5,919,540 - net investing inflow $4,740,006
- Cash used in operations (six months): $(4,705,607)
- Common shares outstanding: 29,383,743 (June 30, 2025)
- Total warrants outstanding at June 30, 2025: 234,930,021 (weighted average exercise $0.30)
- Mezzanine equity (preferred temporary equity): $6,323,667 (June 30, 2025)

Positive aspects (income statement and financials)
- Operating expense control: G&A reduced vs prior periods (personnel and professional services down).
- R&D investment is increasing in line with clinical progress (Phase 2b activity and GLP‑1 muscle‑preservation studies) - aligns costs with value drivers.
- Company converted/sold marketable securities to generate investing cash inflow ($10.66M proceeds H1) that offset cash burn during the period.

Negative aspects (income statement and financials)
- Continued losses: Net loss of $(2.92M) for six months; no product revenue and high dependence on equity financings.
- High non‑cash and preferred costs: Preferred dividends of $1.79M YTD materially increase loss attributable to common stockholders and cash obligations when payable.
- Large warrant & preferred dilution risk: 234.9M warrants and multiple preferred series with aggressive anti‑dilution/full‑ratchet provisions create substantial future dilution and accounting volatility.
- Working capital negative: current liabilities exceed current assets by ~$398K - short runway without new capital.
- Going‑concern flagged: management states "substantial doubt" about ability to continue for 12 months without financing.
- Nasdaq risk: company received a deficiency notice for minimum $1.00 bid price (compliance period through Sept 15, 2025) - potential delisting risk if not remedied.

Operational highlights & risks
- Core programs: Isomyosamine (oral TNF‑α inhibitor - advancing clinical studies including frailty/sarcopenia and GLP‑1 muscle‑preservation work) and Supera‑CBD (synthetic CBD analog).
- Clinical progress attracts spend but no near‑term revenue; success depends on trial results and regulatory approvals.
- Significant governance & capital complexity: multiple convertible preferred series (F, F‑1, G, D), frequent amendments, and deferred installment/redemption schedules - adds execution and financing risk.
- Related‑party and investor relationships noted (e.g., PharmaCyte involvement) and sizable registration/warrant mechanics that can affect future liquidity and shareholder dilution.

Bottom line - what investors should know now
TNF Pharmaceuticals is funding clinical work by drawing down securities and using preferred financings; it has reduced G&A but increased program spend. The balance sheet shows shrinking assets, negative working capital and substantial preferred dividend obligations. Management discloses substantial doubt about the company's ability to continue without additional capital and the company faces a Nasdaq minimum‑bid compliance deadline. If you own or consider buying shares, the situation is high risk: clinical upside exists but is balanced by immediate financing, dilution and listing risks.

If you want, I can prepare a one‑page cash‑runway estimate, dilution scenarios from outstanding preferreds/warrants, or a short checklist of near‑term catalysts and red flags to watch.